INHBE encodes the hepatokine activin E, a key mediator of liver-adipose crosstalk involved in the regulation of lipid metabolism and energy balance. Researchers from Innovent Biologics Co. Ltd. recently released preclinical efficacy data on IBI-3046, a novel RNAi therapeutic targeting INHBE.